JP Morgan Reinstates Overweight on Stoke Therapeutics, Announces $40 Price Target
JP Morgan analyst Jessica Fye reinstates Stoke Therapeutics (NASDAQ:STOK) with a Overweight and announces $40 price target.
Read original at benzingaStocks · News reference
These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results
Stoke Therapeutics (STOK) reported mixed Q2 results with losses of 93 cents per share and sales of $9.325 million. Analysts have mixed opinions.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 4, 2026, 1:28 PM
- Checked
- Aug 4, 2026, 1:28 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Guggenheim Reiterates Buy on Stoke Therapeutics, Maintains $60 Price Target
Guggenheim analyst Yatin Suneja reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $60 price target.
Read original at benzingaWedbush Maintains Outperform on Stoke Therapeutics, Raises Price Target to $40
Wedbush analyst Laura Chico maintains Stoke Therapeutics (NASDAQ:STOK) with a Outperform and raises the price target from $38 to $40.
Read original at benzinga